Erasca, Inc. (ERAS)
14.41
+1.14
(+8.59%)
USD |
NASDAQ |
Nov 06, 16:00
14.52
+0.11
(+0.76%)
After-Hours: 20:00
Erasca Cash from Investing (Quarterly) : 19.49M for June 30, 2026
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 19.49M |
| March 31, 2026 | -243.83M |
| December 31, 2025 | 24.71M |
| September 30, 2025 | 25.70M |
| June 30, 2025 | 15.74M |
| March 31, 2025 | 34.26M |
| December 31, 2024 | 22.62M |
| September 30, 2024 | -102.60M |
| June 30, 2024 | -86.61M |
| March 31, 2024 | 9.971M |
| December 31, 2023 | 4.545M |
| September 30, 2023 | -1.812M |
| June 30, 2023 | -108.67M |
| Date | Value |
|---|---|
| March 31, 2023 | 14.71M |
| December 31, 2022 | -4.867M |
| September 30, 2022 | -55.23M |
| June 30, 2022 | -9.191M |
| March 31, 2022 | -1.794M |
| December 31, 2021 | -63.95M |
| September 30, 2021 | -4.939M |
| June 30, 2021 | 4.46M |
| March 31, 2021 | -0.162M |
| December 31, 2020 | 16.56M |
| September 30, 2020 | -49.15M |
| June 30, 2020 | -39.61M |
| March 31, 2020 | 0.992M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 43.68M |
| Twist Bioscience Corp. | -10.20M |
| Immunome, Inc. | -304.35M |
| Oncolytics Biotech, Inc. | 0.00 |
| Sangamo Therapeutics, Inc. | -0.013M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -27.27M |
| Cash from Financing (Quarterly) | 3.064M |
| Free Cash Flow | -98.08M |
| Free Cash Flow Per Share (Quarterly) | -0.0876 |
| Free Cash Flow to Equity (Quarterly) | -26.04M |
| Free Cash Flow to Firm (Quarterly) | -27.28M |
| Free Cash Flow Yield | -2.30% |